Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A

Ping Zhao1, Caroline A Lee, Kent L Kunze

  • 1Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, La Jolla Laboratories, La Jolla, California, USA. pingz@sonuspharma.com

Insights

The metabolite MA, not the parent drug diltiazem, is the primary cause of CYP3A inactivation. This highlights the inadequacy of using only parent drug parameters to predict drug metabolism changes in the liver.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Enzyme Kinetics

Background:

  • Microsomal kinetic parameters are frequently used to predict time-dependent drug inactivation.
  • Previous studies indicated that diltiazem's microsomal parameters underestimated CYP3A inactivation in hepatocytes.

Purpose of the Study:

  • To investigate the roles of diltiazem and its metabolites (MA and MD) in CYP3A inactivation and reversible inhibition.
  • To determine the contribution of these compounds to CYP3A loss in human liver microsomes and hepatocytes.

Main Methods:

  • Assessed time-dependent inactivation kinetics (k(inact), K(I)) of diltiazem, MA, and MD on CYP3A in human liver microsomes.
  • Evaluated reversible inhibition of CYP3A by MA and MD.
  • Incubated diltiazem in cryopreserved human hepatocytes to monitor CYP3A activity, metabolite formation, and intracellular accumulation.

Main Results:

  • MA was a more potent CYP3A inactivator than diltiazem in microsomes; MD did not cause inactivation.
  • Diltiazem inactivation was microsomal protein-dependent, while MA inactivation was not.
  • MA and MD acted as competitive reversible inhibitors of CYP3A.
  • In hepatocytes, diltiazem treatment led to MA/MD formation and CYP3A loss, with MA levels near its K(I).

Conclusions:

  • Time-dependent inactivation of CYP3A by the metabolite MA is the main driver of CYP3A loss.
  • Predicting CYP3A loss solely based on the parent drug's microsomal inactivation parameters is insufficient.
  • Metabolite activity and intracellular accumulation are critical factors in drug-induced enzyme inactivation.

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Chronopharmacokinetics: Time-Dependent Pharmacokinetics01:20

Chronopharmacokinetics: Time-Dependent Pharmacokinetics

Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...